Sung Hye Kong1, Jung Hee Kim1, Sang Wan Kim1,2, Chan Soo Shin3. 1. Department of Internal Medicine, Seoul National University College of Medicine, 101 Dae-hak ro, Jongno gu, Seoul, 03080, Republic of Korea. 2. Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea. 3. Department of Internal Medicine, Seoul National University College of Medicine, 101 Dae-hak ro, Jongno gu, Seoul, 03080, Republic of Korea. csshin@snu.ac.kr.
Abstract
INTRODUCTION: Aromatase inhibitors are known to accelerate bone loss in patients with breast cancer. However, how much AIs affect the efficacy of antiresorptive agents has not been studied. The study aimed to compare the effect of alendronate on bone mineral density (BMD) between patients with and without AI treatment. MATERIALS AND METHODS: In this retrospective study, 90 postmenopausal women with early breast cancer who were being treated with both AI and alendronate 70 mg weekly (ALN + AI), and 90 age- and body mass index (BMI)-matched patients who were only taking alendronate (ALN-only) were analyzed. BMD and bone turnover markers (BTMs) were assessed at the baseline and 12 months. RESULTS: The mean age was 63 years. At baseline, the ALN-only group had lower lumbar spine (LS), femur neck (FN), and total hip (TH) BMD than ALN + AI group. After 1-year of alendronate treatment, the LS and FN BMD were improved more in the ALN-only group than those in the ALN + AI group after adjustments for age, BMI, baseline BMD, diabetes, hypertension, renal function, and previous fracture history [LS BMD: 6.2% (3.1%; 9.2%) in ALN-only, 3.5% (-0.5%; 6.5%) in ALN + AI, p = 0.001; FN BMD: 2.5% (0.3%; 5.7%) in ALN-only, 0.9% (- 1.8%; 3.6%) in ALD + AI, p = 0.032]. BTMs were significantly decreased in both groups, but the changes between groups were similar. CONCLUSION: The effect of alendronate on the LS and FN BMD was attenuated in postmenopausal women who were taking AI compared to those who were not on AI.
INTRODUCTION: Aromatase inhibitors are known to accelerate bone loss in patients with breast cancer. However, how much AIs affect the efficacy of antiresorptive agents has not been studied. The study aimed to compare the effect of alendronate on bone mineral density (BMD) between patients with and without AI treatment. MATERIALS AND METHODS: In this retrospective study, 90 postmenopausal women with early breast cancer who were being treated with both AI and alendronate 70 mg weekly (ALN + AI), and 90 age- and body mass index (BMI)-matched patients who were only taking alendronate (ALN-only) were analyzed. BMD and bone turnover markers (BTMs) were assessed at the baseline and 12 months. RESULTS: The mean age was 63 years. At baseline, the ALN-only group had lower lumbar spine (LS), femur neck (FN), and total hip (TH) BMD than ALN + AI group. After 1-year of alendronate treatment, the LS and FN BMD were improved more in the ALN-only group than those in the ALN + AI group after adjustments for age, BMI, baseline BMD, diabetes, hypertension, renal function, and previous fracture history [LS BMD: 6.2% (3.1%; 9.2%) in ALN-only, 3.5% (-0.5%; 6.5%) in ALN + AI, p = 0.001; FN BMD: 2.5% (0.3%; 5.7%) in ALN-only, 0.9% (- 1.8%; 3.6%) in ALD + AI, p = 0.032]. BTMs were significantly decreased in both groups, but the changes between groups were similar. CONCLUSION: The effect of alendronate on the LS and FN BMD was attenuated in postmenopausal women who were taking AI compared to those who were not on AI.
Entities:
Keywords:
Alendronate; Aromatase inhibitor; Bone mineral density; Treatment effect
Authors: S L Greenspan; K T Vujevich; A Brufsky; B C Lembersky; G J van Londen; R C Jankowitz; S L Puhalla; P Rastogi; S Perera Journal: Osteoporos Int Date: 2015-03-20 Impact factor: 4.507
Authors: Catherine Van Poznak; Rosemary A Hannon; John R Mackey; Mario Campone; Justus P Apffelstaedt; Glen Clack; David Barlow; Andreas Makris; Richard Eastell Journal: J Clin Oncol Date: 2010-01-11 Impact factor: 44.544
Authors: Richard Eastell; Judith E Adams; Robert E Coleman; Anthony Howell; Rosemary A Hannon; Jack Cuzick; John R Mackey; Matthias W Beckmann; Glen Clack Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: Anna J Lomax; Saw Yee Yap; Karen White; Jane Beith; Ehtesham Abdi; Adam Broad; Sanjeev Sewak; Chooi Lee; Philip Sambrook; Nicholas Pocock; Margaret J Henry; Elaine G Yeow; Richard Bell Journal: J Bone Oncol Date: 2013-08-15 Impact factor: 4.072
Authors: David L Waning; Khalid S Mohammad; Steven Reiken; Wenjun Xie; Daniel C Andersson; Sutha John; Antonella Chiechi; Laura E Wright; Alisa Umanskaya; Maria Niewolna; Trupti Trivedi; Sahba Charkhzarrin; Pooja Khatiwada; Anetta Wronska; Ashley Haynes; Maria Serena Benassi; Frank A Witzmann; Gehua Zhen; Xiao Wang; Xu Cao; G David Roodman; Andrew R Marks; Theresa A Guise Journal: Nat Med Date: 2015-10-12 Impact factor: 53.440
Authors: J E Lester; D Dodwell; J E Brown; O P Purohit; S A Gutcher; S P Ellis; R Thorpe; J M Horsman; R E Coleman Journal: J Bone Oncol Date: 2012-07-11 Impact factor: 4.072